Sort by:

• Highly Influential Citations
• Citations
• Acceleration
• Velocity
• Recency

Learn More

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

• Kathy D. Miller, Molin Wang, +6 authors N. Davidson
• The New England journal of medicine
• 2007

BACKGROUND In an open-label, randomized, phase 3 trial, we compared the efficacy and safety of paclitaxel with that of paclitaxel plus bevacizumab, a monoclonal antibody against vascular endothelial… (More)

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

• Edward H. Romond, Edith A. Perez, +22 authors Norman Wolmark
• The New England journal of medicine
• 2005

BACKGROUND We present the combined results of two trials that compared adjuvant chemotherapy with or without concurrent trastuzumab in women with surgically removed HER2-positive breast cancer. … (More)

A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.

• P. J. E. Goss, James N. Ingle, +15 authors Joseph L. Pater
• The New England journal of medicine
• 2003

BACKGROUND In hormone-dependent breast cancer, five years of postoperative tamoxifen therapy--but not tamoxifen therapy of longer duration--prolongs disease-free and overall survival. The aromatase… (More)

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

• P. J. E. Goss, James N. Ingle, +15 authors Joseph L. Pater
• Journal of the National Cancer Institute
• 2005

BACKGROUND Most recurrences in women with breast cancer receiving 5 years of adjuvant tamoxifen occur after 5 years. The MA.17 trial, which was designed to determine whether extended adjuvant therapy… (More)

Estrogen carcinogenesis in breast cancer.

• James D. Yager, N. Davidson
• The New England journal of medicine
• 2006

N Engl J Med 2006;354:270-82. Copyright © 2006 Massachusetts Medical Society. n this article, we review recent findings related to estrogen exposure and the risk of breast cancer, the mechanisms that… (More)

Steady states, charge movements, and rates for a cloned GABA transporter expressed in Xenopus oocytes.

• Sarah M. Mager, Jörg Naeve, M Quick, Cesar G. Labarca, N. Davidson, Henry A. Lester
• Neuron
• 1993

Voltage-clamp analysis was applied to study the currents associated with the uptake of extracellular gamma-aminobutyric acid (GABA) by the cloned transporter GAT1 expressed at high efficiency in… (More)

Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses.

• Damien Berg, N. Davidson, +6 authors Donna M. Rennick
• The Journal of clinical investigation
• 1996

We have characterized the progressive stages of chronic intestinal inflammation that develops spontaneously in specific pathogen-free (SPF) mice with a targeted disruption in the IL-10 gene… (More)

Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer:…

• Marc L. Citron, Donald A. Berry, +18 authors Larry Norton
• Journal of clinical oncology : official journal…
• 2003

PURPOSE Using a 2 x 2 factorial design, we studied the adjuvant chemotherapy of women with axillary node-positive breast cancer to compare sequential doxorubicin (A), paclitaxel (T), and… (More)

Novel pore-lining residues in CFTR that govern permeation and open-channel block.

• Suzanne McDonough, N. Davidson, Henry A. Lester, Nami McCarty
• Neuron
• 1994

The cystic fibrosis transmembrane conductance regulator (CFTR) is both a member of the ATP-binding cassette superfamily and a Cl(-)-selective ion channel. We investigated the permeation pathway of… (More)

Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update.

• James L Khatcheressian, P. J. Hurley, +11 authors N. Davidson
• Journal of clinical oncology : official journal…
• 2013

PURPOSE To provide recommendations on the follow-up and management of patients with breast cancer who have completed primary therapy with curative intent. METHODS To update the 2006 guideline of… (More)

• ‹
• 1
• 2
• 3
• 4
• 5
• ›